Clinical Trial

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Name: Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia — clinical trial record (NCT06082934)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

Trial Details

NCT Number	NCT06082934
Lead Sponsor	Xijing Hospital
Conditions	Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Enrollment	30 participants
Start Date	2023-11-01
Primary Completion	2026-11-01 (estimated)
Study Completion	2026-11-01 (estimated)
Updated on ClinicalTrials.gov	2023-10-13